高级搜索

30 Gy/10f术前放疗后直肠癌组织中VEGF和VEGFR-2表达的临床病理学研究

彭亦凡, 王林, 顾晋

彭亦凡, 王林, 顾晋. 30 Gy/10f术前放疗后直肠癌组织中VEGF和VEGFR-2表达的临床病理学研究[J]. 肿瘤防治研究, 2012, 39(08): 918-922. DOI: 10.3971/j.issn.1000-8578.2012.08.009
引用本文: 彭亦凡, 王林, 顾晋. 30 Gy/10f术前放疗后直肠癌组织中VEGF和VEGFR-2表达的临床病理学研究[J]. 肿瘤防治研究, 2012, 39(08): 918-922. DOI: 10.3971/j.issn.1000-8578.2012.08.009
Peng Yifan, Wang Lin, Gu Jin. Clinic Pathology Study on Expression of VEGF and VEGFR-2 in Rectal Cancer Treated with 30 Gy/10f Preoperative Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 918-922. DOI: 10.3971/j.issn.1000-8578.2012.08.009
Citation: Peng Yifan, Wang Lin, Gu Jin. Clinic Pathology Study on Expression of VEGF and VEGFR-2 in Rectal Cancer Treated with 30 Gy/10f Preoperative Radiotherapy[J]. Cancer Research on Prevention and Treatment, 2012, 39(08): 918-922. DOI: 10.3971/j.issn.1000-8578.2012.08.009

30 Gy/10f术前放疗后直肠癌组织中VEGF和VEGFR-2表达的临床病理学研究

详细信息
    作者简介:

    彭亦凡(1972-),男,博士,副主任医师,主要从事结直肠癌转移复发机制的研究

    通讯作者:

    顾晋,E-mail:China.zlguj@yahoo.com.cn

  • 中图分类号: R735.3+7;R730.55

Clinic Pathology Study on Expression of VEGF and VEGFR-2 in Rectal Cancer Treated with 30 Gy/10f Preoperative Radiotherapy

  • 摘要: 目的 探讨术前放疗后直肠癌组织中VEGF和VEGFR-2表达的改变对临床预后的影响。方法收集我院自2002年8月—2007年12月接受术前放疗(30 Gy/10 f)并行开腹根治性手术的直肠癌患者116例,应用免疫组织化学的方法检测患者肿瘤组织中VEGF和VEGFR-2的表达,分析其对患者临床预后的影响。结果VEGF的阳性表达率为74.1% (86/116),VEGFR-2的阳性表达率为42.2%(49/116),单因素和多因素分析均表明淋巴结转移(ypN分期)和VEGF表达情况是远处转移的独立风险因素;单因素分析表明VEGF和VEGFR-2的表达情况、淋巴结转移(ypN分期)、肿瘤侵犯深度(ypT分期)与患者的3年无病生存率有显著相关性(P<0.05);多因素分析表明VEGF表达情况、淋巴结转移(ypN分期)是影响直肠癌术前放疗后患者3年无病生存率的主要因素。结论30 Gy/10 f术前放疗后VEGF的表达与临床预后有显著的相关性。

     

    Abstract: Objective To analyze the prognostic value of vascular endothelial growth factor (VEGF)and Vascular Endothelial Growth Factor Receptor-2(VEGFR-2) in patients with rectal cancer treated with 30 Gy/10 f preoperative radiotherapy and radical surgery. Methods One hundred and sixteen patients with clinical stage Ⅲ rectal cancer from Aug.2002 to Dec.2007 were studied.All patients underwent radical surgery after 30 Gy/10 f preoperative radiotherapy.Immunohistochemical examination of VEGF and VEGFR-2 were performed on the reselected tumor specimen.An immunohistochemical score established from the extension and intensity of the markers was used for analysis.The log rank test and proportional hazards regression analysis were used to calculate the probability of this biomarker associated with patients′ prognosis. Results The expressions of VEGF and VEGFR-2 were identified in 74.1% (86/116) and 42.2% (49/116) of patients.Univariate and multivariate analysis showed that lymph node metastasis (ypN stage) and positive VEGF expression were the independent risk factors for distant metastasis.Univariate analysis showed that positive expressions of VEGF and VEGFR-2,lymph node metastasis (ypN stage) and tumor invasion depth (ypT stage) were correlated with decreased 3-year disease-free survival rate (P<0.05).In multivariate survival analysis,positive VEGF staining and ypN+ stage were the independent prognostic factors for disease-free survival.Subgroup analyses showed the expression of VEGF was significantly associated with the increased distant metastasis rate and decreased DFS in patients with ypN+ stage. Conclusion VEGF expression may have potential value for predicting distant metastasis and disease-free survival in rectal cancer after 30 Gy/10 f preoperative radiotherapy.Inhibition of VEGF in combination with radiotherapy may improve the patients′ prognosis.

     

  • [1] Jemal A,Siegel R,Ward E,et al.Cancer statistics,2009[J].CA Cancer J Clin,2009,59(4):225-49.
    [2] Li M,Gu J.Changing patterns of colorectal cancer in China over a period of 20 years[J].World JGastroenterol,2005,11(30):4685-8.
    [3] Glynne-Jones R,Mathur P,Elton C,et al.The multidisciplinary management of gastrointestinalcancer.Multimodal treatment of rectal cancer[J].Best Pract Res Clin Gastroenterol,2007,21(6):1049-70.
    [4] Sebag-Montefiore D,Bujko K,Valentini V.Rectal cancer multidisciplinary management:evidences andfuture landscape[J].Radiother Oncol,2009,92(2):145-7.
    [5] Wille-Jrgensen P,Bülow S.The multidisciplinary team conference in rectal cancer--a stepforward[J].Colorectal Dis,2009,11(3):231-2.
    [6] Bisceglia G,Mastrodonato N,Rucci B,et al.Effectiveness of neoadjuvant radiotherapy in thetreatment of locally advanced rectal cancer:a single-center experience in 263 patients[J].DigSurg,2010,27(3):217-23.
    [7] Valentini V,Aristei C,Glimelius B,et al.Multidisciplinary Rectal Cancer Management:2nd EuropeanRectal Cancer Consensus Conference (EURECA-CC2)[J].Radiother Oncol,2009,92(2):148-63.
    [8] Peeters KC,Marijnen CA,Nagtegaal ID,et al.The TME trial after a median follow-up of 6years:increased local control but no survival benefit in irradiated patients with resectable rectalcarcinoma[J].Ann Surg,2007,246(5):693-701.
    [9] Bosset JF,Collette L,Calais G,et al.Chemotherapy with preoperative radiotherapy in rectal cancer[J].N Engl J Med,2006,355(11):1114-23.
    [10] Sauer R,Becker H,Hohenberger W,et al.Preoperative versus postoperative chemoradiotherapy forrectal cancer[J].N Engl J Med,2004,351(17):1731-40.
    [11] Sebag-Montefiore D,Stephens RJ,Steele R,et al.Preoperative radiotherapy versus selectivepostoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016):amulticentre,randomised trial[J].Lancet,2009,373(9666):811-20.
    [12] Camma C,Giunta M,Fiorica F,et al.Preoperative radiotherapy for resectable rectal cancer:A meta-analysis[J].JAMA,2000,284(8):1008-15.
    [13] Colorectal Cancer Collaborative Group.Adjuvant radiotherapy for rectal cancer:a systematicoverview of 8,507 patients from 22 randomised trials[J].Lancet,2001,358(9290):1291-304.
    [14] Heald RJ,Ryall RD.Recurrence and survival after total mesorectal excision for rectal cancer[J].Lancet,1986,1(8496):1479-82.
    [15] Galizia G,Lieto E,Ferraraccio F,et al.Determination of molecular marker expression can predictclinical outcome in colon carcinomas[J].Clin Cancer Res,2004,10(10):3490-9.
    [16] Roskoski R Jr.Vascular endothelial growth factor (VEGF) signaling in tumor progression[J].Crit Rev Oncol Hematol,2007,62(3):179-213.
    [17] Gupta VK,Jaskowiak NT,Beckett MA,et al.Vascular endothelial growth factor enhances endothelialcell survival and tumor radioresistance[J].Cancer J,2002,8(1):47-54.
    [18] Gorski DH,Beckett MA,Jaskowiak NT,et al.Blockage of the vascular endothelial growth factorstress response increases the antitumor effects of ionizing radiation[J].Cancer Res,1999,59(14):3374-8.
    [19] Nieder C,Wiedenmann N,Andratschke N,et al.Current status of angiogenesis inhibitors combinedwith radiation therapy[J].Cancer Treat Rev,2006,32(5):348-64.
    [20] Giatromanolaki A,Sivridis E,Koukourakis MI.Angiogenesis in colorectal cancer:prognostic andtherapeutic implications[J].Am J Clin Oncol,2006,29(4):408-17.
    [21] Giralt J,Navalpotro B,Hermosilla E,et al.Prognostic significance of vascular endothelial growthfactor and cyclooxygenase-2 in patients with rectal cancer treated with preoperative radiotherapy[J].Oncology,2006,71(5-6):312-9.
    [22] Nozue M,Isaka N,Fukao K.Over-expression of vascular endothelial growth factor afterpreoperative radiation therapy for rectal cancer[J].Oncol Rep,2001,8(6):1247-9.
    [23] Yancopoulos GD,Davis S,Gale NW,et al.Vascular-specific growth factors and blood vesselformation[J].Nature,2000,407(6801):242-8.
    [24] Winkler F,Kozin SV,Tong RT,et al.Kinetics of vascular normalization by VEGFR2 blockade governsbrain tumor response to radiation:role of oxygenation,angiopoietin-1,and matrix metalloproteinases[J].Cancer Cell,2004,6(6):553-63.
    [25] Li J,Huang S,Armstrong EA,et al.Angiogenesis and radiation response modulation after vascularendothelial growth factor receptor-2 (VEGFR2) blockade[J].Int J Radiat Oncol Biol Phys,2005,62(5):1477-85.
    [26] Kozin SV,Boucher Y,Hicklin DJ,et al.Vascular endothelial growth factor receptor-2-blockingantibody potentiates radiation-induced long-term control of human tumor xenografts[J].CancerRes,2001,61(1):39-44.
    [27] Lee CG,Heijn M,di Tomaso E,et al.Anti-Vascular endothelial growth factor treatment augmentstumor radiation response under normoxic or hypoxic conditions[J].Cancer Res,2000,60(19):5565-70.
计量
  • 文章访问数:  2739
  • HTML全文浏览量:  20
  • PDF下载量:  578
  • 被引次数: 0
出版历程
  • 收稿日期:  2012-02-21
  • 修回日期:  2012-05-27
  • 刊出日期:  2012-08-24

目录

    /

    返回文章
    返回
    x 关闭 永久关闭